Giloy and liver safety: what the case reports actually say

Giloy went from a specialist Ayurvedic herb to one of the most consumed supplements in India in about a year. Shortly afterwards, a cluster of published case reports described liver injury in people who had been taking it.

That sequence produced a predictable response on both sides: alarmed headlines on one, and flat denial from parts of the industry on the other. Neither is a useful position for someone deciding whether to take it or manufacture it.

This article sets out what the reports actually described, the substantive criticisms of them, and what we think a defensible position looks like.

This is information for people making decisions about products, not medical advice. If you are taking giloy and develop jaundice, persistent nausea or pain under the right ribs, stop and see a doctor.

What giloy is

Tinospora cordifolia, called guduchi or amrita in the classical texts, where it is regarded as one of the principal rasayana herbs. The stem is the part traditionally used. It has a long record of traditional use and was consumed at an enormous scale in India from 2020 onwards.

What the case reports described

Published case series described patients presenting with liver injury, a pattern consistent with autoimmune-like hepatitis in a number of them, who had a history of consuming Tinospora cordifolia preparations. Investigators applied causality assessment tools and, after excluding other common causes, considered the herb a probable contributor in several cases.

The reports came mostly from Indian liver units during the period when giloy consumption was at its peak, and most patients recovered after stopping the product and receiving treatment.

That is the substance of it. It is a real finding published in peer-reviewed literature, and dismissing it is not honest.

The criticisms of those reports, which are also substantive

Several qualified objections were raised, and they deserve equal weight.

Product identity was often not verified. In most cases the actual material consumed was not available for botanical analysis. Patients had taken commercial products, home preparations, or material identified as giloy by a supplier. Whether it was genuinely Tinospora cordifolia, and only that, was frequently unestablished.

Adulteration and substitution are real. Tinospora crispa, a related species, has been associated with hepatotoxicity more clearly, and substitution between Tinospora species occurs in commerce. Some commercial products are also multi-herb formulations where giloy is one of several ingredients.

Contamination was not excluded. Heavy metals and undeclared additions are documented problems in parts of the Indian herbal supply chain. Without testing the consumed material, these cannot be ruled out.

The denominator is enormous. Giloy was consumed by a very large number of people over that period. A small number of case reports against that background does not establish a high rate of risk, though it also does not establish safety.

Causality assessment has limits. The tools used are the standard approach for suspected drug-induced liver injury, and they produce a probability judgement rather than proof.

So what is a reasonable conclusion?

Holding both of those honestly, here is where we land.

The case reports are not sufficient to conclude that properly identified, properly sourced Tinospora cordifolia is hepatotoxic at normal doses.

They are sufficient to say that the question is open, that susceptible individuals may exist, and that treating giloy as risk-free indefinite daily consumption is not warranted.

That is an unsatisfying answer, and it is the accurate one. A lot of the commentary on this subject, in both directions, is more certain than the evidence allows.

What this means in practice

If you are taking giloy

Take a defined course rather than indefinite daily use. This is the single most practical adjustment. The traditional use of rasayana herbs was generally in courses, not as permanent additions to the diet.

Do not take it if you have existing liver disease without your doctor’s agreement. The organ you are concerned about is not the one to take an open question with.

Tell your doctor you are taking it, particularly if you are on any regular medication.

Stop and seek advice if you develop yellowing of the eyes or skin, dark urine, persistent nausea, unusual fatigue or discomfort under the right ribs.

Buy from a source that can tell you what is in it. Which leads to the next section.

If you are manufacturing giloy products

This is where we have an obligation to be direct, because several of the criticisms above are about manufacturing rather than about the plant.

Botanical identity testing is not optional here. Substitution between Tinospora species is documented, and T. crispa has a worse safety profile. Confirming you are supplying T. cordifolia is a basic requirement, not a premium feature.

Use stem material, not leaf. The classical preparations specify stem, and that is where the recognised constituents concentrate. Leaf material is cheaper and should be treated as a substitution.

Test every lot for heavy metals. Contamination is a documented problem in this supply chain and it is a confound in the case reports themselves.

Print a defined course on the label, not open-ended daily use. We print this on ours.

Print the liver caution. Anyone with a liver condition should be told to consult a doctor before use. Most giloy products on the Indian shelf do not carry this, and we think that is a failure rather than a judgement call.

A manufacturer who responds to published safety literature by saying nothing is leaving the brand owner holding a risk they were not told about.

Why we still make it

Some readers will reasonably ask why, given the above, we supply giloy at all.

Because the evidence does not support withdrawing a herb with a long traditional record on the basis of case reports where the material was mostly unverified, and because the practical response to those reports is better manufacturing, clearer labelling and defined courses, all of which are available.

What we will not do is pretend the literature does not exist, or print indefinite-use instructions, or supply material we have not identified botanically. Those three things are what the case reports should actually change.

What a giloy label may and may not claim

Available: traditional use as a rasayana, immune support in general wellness terms, composition and stem-extract specification.

Not available: claims to prevent or treat infection or any disease, claims about immunity in a disease-preventing sense, and any promise of a specific outcome.

The short version

Published case reports described liver injury in people taking giloy, and they are real. The reports also mostly could not verify what the patients had actually consumed, and species substitution, multi-herb products and contamination are all documented problems. So the question is open rather than settled.

The sensible response: defined courses rather than indefinite use, avoid it with existing liver disease, tell your doctor, and buy from a supplier who tests botanical identity and heavy metals. If you manufacture it, do those tests and print the caution.

For sourcing detail see the giloy ingredient page, and for how we handle lot-level testing, raw material sourcing.